SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira Pharmaceuticals, Inc. and Certain Officers - PCRX

NEW YORK, NY--(Marketwired - Nov 28, 2014) - Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") ( NASDAQ : PCRX ) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

If you are a shareholder who purchased Pacira securities during the Class Period, you have until December 2, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Pacira is a specialty pharmaceutical company that develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. Its product pipeline includes EXPAREL, which has completed Phase III clinical trials for postsurgical analgesia-nerve block administration.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, prospects and performance. Specifically, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was overstating the efficacy of its Exparel drug; (ii) the Company was improperly promoting its Exparel drug by touting its ability to be effective for up to 72 hours, when in fact, it is only approved for 24 hours of pain relief; (iii) the Company improperly claimed that Exparel is safe for use in cholecystectomy and colectomy procedures, when in fact, approved labeling does not provide instructions for, or indicate that Exparel will be safe and effective for postsurgical pain, if used in surgical procedures other than hemorrhoidectomy or bunionectomy; (iv) a substantial portion of the Company's revenues were derived from off label marketing; and (v) and as a result of the above, the Company's financial statements were materially false and misleading at all relevant times. 

On September 25, 2014, the Company announced that it received a Warning Letter from the U.S. Food and Drug Administration's ("FDA") Office of Prescription Drug Promotion ("OPDP") referencing certain promotional materials relating to Exparel (the "Warning Letter"). In the Warning Letter, the FDA's OPDP stated that it has evidence that Exparel has been promoted for uses for which it does not have approval, and for which its labeling does not provide adequate directions for use, thus rendering Exparel "misbranded." The FDA noted that Pacira's advertising materials suggested that Exparel is safe and effective for use in cholecystectomy and colectomy procedures. However, the FDA said that the approved labeling for Exparel does not provide instructions for, or indicate that Exparel will be safe and effective for postsurgical pain, if used in surgical procedures other than a hemorrhoidectomy or bunionectomy. Further, the Warning Letter noted that a journal advertisement by Pacira claimed Exparel was able to provide pain-relief for up to 72 hours, while the drug is only approved for pain-relief up to 24 hours. The agency said these claims overstate Exparel's efficacy and are misleading.

On the news, Pacira stock fell $11.66, or almost 11%, on unusually heavy volume, to close at $94.62 on September 25, 2014.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com .

CONTACT: Robert S. Willoughby Pomerantz LLP Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 224

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 139

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Radiation Hardened Electronics Sector

Updated Category News Views 124

Radiation Hardened Electronics Market Size & Insights Austin - The Radiation Hardened Electronics market has been drawing significant attention as it evolves rapidly. It was valued at USD 1.60 billion recently and is projected to reach USD 2.35 billion within a few years, indicating noteworthy growth driven by an impressive CAGR of 4.45% between 2024 and 2032. Factors...

Continue Reading
Understanding the Growing Investment Trends in Philip Morris

Updated Category News Views 249

Investment Trends Surrounding Philip Morris International Investors with significant capital are taking a positive stance toward Philip Morris International (NYSE: PM), a situation that is essential for market watchers to note. Today, significant activity in options trading has come to light, indicating substantial interest from major players. While the identities of...

Continue Reading
Alibaba Enhances Cross-Border Trade with New AI Features

Updated Category News Views 294

Alibaba's Commitment to AI Development Alibaba Group Holding Limited (NYSE: BABA) is making significant strides in the artificial intelligence (AI) sector. The company is introducing innovative AI tools across its global marketplaces and mobile applications, aiming to enhance the efficiency of cross-border trade while providing users with more intuitive shopping...

Continue Reading
Apache Software Foundation Elevates New Software Projects

Updated Category News Views 219

Apache Software Foundation Welcomes New Projects The Apache Software Foundation (ASF), a passionate hub for open-source software, has officially recognized Apache DevLake and Apache Grails as its latest Top-Level Projects (TLPs). This milestone marks a significant achievement for both projects, unveiling new opportunities in the software development landscape. Introducing...

Continue Reading
How Strategic Finance Consulting Prepares Companies for Growth

Updated Category Business Views 67

Growth rarely strains one area at a time. It pulls on hiring, pricing, inventory, and payment timing all at once, while leaders still need clear signals from the numbers. Reports that worked during an earlier stage can start missing key risks. Companies preparing for expansion benefit from stronger financial judgment, steadier planning, and a clearer view of what daily...

Continue Reading